Cardiovascular disease is common among patients with Treatment for Stage 3 CKD

Treatment for Stage 3 CKD

Treatment for Stage 3 CKD is associated with an increased risk of cardiovascular disease and chronic renal failure. Kidney disease is the ninth leading cause of death in the United States.

Cardiovascular disease is common among patients with Treatment for Stage 3 CKD . While the risks of cardiovascular disease and death are highest among those requiring dialysis, earlier stages of chronic kidney disease also are associated with cardiovascular disease.2–4

Furthermore, if kidney disease were considered a coronary heart disease equivalent, more than 85% of those with stage 3, 4, or 5 disease would qualify for lipid-lowering therapy by LDL-C criteria.6
In Treatment for Stage 3 CKD, the kidneys are damaged and/or cannot filter blood normally.1 CKD increases the risk for many adverse health outcomes, including cardiovascular disease, end-stage renal disease (ESRD), and mortality. However, Treatment for Stage 3 CKD is usually asymptomatic until its most advanced state.

Treatment for Stage 3 CKD may involve some mild dietary changes (a lower protein diet may in some cases be recommended), and a blood pressure medication may be prescribed (usually of the ACE inhibitor class, the angiotensin II receptor class, or both, even if blood pressure is not really elevated much).

Kidney function is measured by the Glomerular Filtration Rate (GFR) defining the renal excretion capacity. Based on the GFR and protein excretion, the disease is categorized into five CKD stages. The first two CKD stages (GFR value >60) only indicate kidney disease in conjunction with increased protein excretion levels suggesting a higher risk of further damage to the kidney function. Moderate to severe impairment of the kidney function is described as CKD stages 3-4. CKD stage 5 is defined as (nearly) complete loss of kidney function.

http://www.sjzkidneyhospital.com/tags.php?/CKD+Treatment/